On June 8th, 2021, the IBS AngelTM Iron Bioresorbable Scaffold System, innovated by Biotyx Medical (Shenzhen) Co., Ltd., was awarded the registration certificate that was issued by the Malaysian Medical Device Authority (MDA).

In early March 2020, Biotyx representatives and American expert Dr. Daniel McLennan went to Kuala Lumpur, Malaysia to conduct academic exchanges friendly with Dr. Mazeni Alwi and Dr. Koh Ghee Tiong, well-known in the field of cardiac intervention. The topic focuses on the clinical application experience of the IBS Angel™ iron bioabsorbable scaffold independently developed by Biotyx.

On January 8th, 2020, the 9th Viet Nam Congress of Congenital and Structural Heart Disease was grandly held in Ho Chi Minh City, Vietnam. The implantation surgery of IBS Angel™ iron bioabsorbable scaffold, independently developed by Biotyx, has achieved great success. The present experts in the cardiovascular field gave a high evaluation of IBS Angel™.

From June 26th to 29th, 2019, the Congenital, Structural and Valvular Heart Disease Interventional Treatment Conference (CSI Frankfurt 2019) was grandly held in Frankfurt, Germany. The world premiere implantation surgery of the IBS Angel™ iron bioabsorbable scaffold independently developed by Biotyx, has become the academic highlight of the audience.

From March 28th to 31st, 2019, the 17th China Interventional Therapeutics (CIT 2019) was grandly held at the Beijing National Convention Center. Biotyx Medical(Shenzhen) Co., Ltd. was invited to participate in this academic event, and a satellite meeting was held during the meeting to show the participants its strong innovative strength.

From September 21st to 25th, 2018, the 30th American Transcatheter Cardiovascular Therapeutics (TCT 2018) was held in San Diego, USA. As the pride of the industry's leading innovative cardiovascular minimally invasive interventional medical device company and national brand, Biotyx Medical (Shenzhen) Co., Ltd. has brought IBS®™ sirolimus-eluting iron bioresorbable coronary scaffold, developed over 12 years, to participate in this world advanced meeting in the field of cardiovascular intervention